The AI operating system for target discovery.
AVATAR ranks the most druggable, deliverable targets — grounded in 20+ years of in-vivo-validated proteomic data.
| Target | Tissue | Accessibility | Druggability | Confidence | Recommended modality |
|---|---|---|---|---|---|
| ANXA1 (truncated) | Tumor endothelium | 92 | 88 | 94 | Antibody / ADC |
| APP2 | Lung microvascular | 90 | 87 | 91 | Antibody / bispecific |
| — | — | — | — | — | — |
| — | — | — | — | — | — |
Four modules, one workflow.
Data Ingestion
Upload mass-spec results, proteomic datasets, or target lists in standard formats. AVATAR handles the plumbing so your team doesn't rebuild pipelines per project.
AI Target Ranking
Models trained on 20+ years of vascular-accessibility data score every candidate on druggability, tissue accessibility, and delivery-format fit — with the evidence behind each call.
Delivery-Format Match
Match ranked targets to antibody, ADC, or nanoparticle formats using in-vivo data on what actually crosses the endothelium. Stop paying for reformulations later.
Validation Loop
Top-ranked targets flow into our wet lab — antibody generation, analytical QC, SPECT/CT, intravital microscopy — so a ranking is a validation, not a guess.
What the science behind AVATAR has already proven.
Four in-house programs: two build on foundational discoveries from PRISM's research; two are newer bispecific companion programs designed using AVATAR directly.
CAV-AnnA1-001
Truncated Annexin A1 was identified as a tumor-endothelium delivery target through research at PRISM — validated in vivo and published in Nature Medicine, 2014. AVATAR is built to rank targets like this one, systematically and at scale.
CAV-AnnA1-002
Bispecific companion program: pairs an AVATAR-nominated tumor-endothelium binder with a payload arm engineered for solid-tumor kill, using the same accessibility-first target logic.
CAV-APP2-001
Aminopeptidase P2 was identified as a lung-caveolae delivery target through research at PRISM — mechanism confirmed by caveolin-1 knockdown, published in J. Vascular Research, 2010, and extended to nanoparticle delivery in Nature Nanotechnology, 2024 (Nayak/Chrastina et al.). AVATAR is built to rank targets like this one, systematically and at scale.
CAV-APP2-002
Bispecific companion program: pairs an AVATAR-nominated lung-microvascular binder with a therapeutic arm for tissue-restricted delivery at ultra-low doses.
See AVATAR on your data.
We'll walk you through the platform against a target — or a tissue — you have in mind.